Company: PETVW
Filing Date: 2025-07-10
Form Type: 10-K
Source: 0001641172-25-018617
Chunk: 19

Company: PetVivo Holdings, Inc.
Filing Date: 2025-07-10
Form: 10-K
Item: Item 1
Chunk 19
---
 exported. Some countries do not have medical
device regulations, but in most foreign countries medical devices are regulated. Frequently, medical device companies may choose to seek
and obtain regulatory approval of a device in a foreign country prior to application in the U.S. given the different regulatory requirements.
However, this does not ensure approval of a device in the U.S.

Research
and Development

The
Company is currently pursuing advancements in the composition, methods of manufacture and use for its proprietary biomaterials. It is
anticipated that within the next twelve months the Company will pursue additional third-party studies related to the use of Spryng®
for the treatment of osteoarthritis in canine and equine patients. The Company also anticipates that resources will be expended to advance
and improve the manufacturing systems for Spryn® that will increase product volume and overall efficiency. Finally, the
Company anticipates that research and testing will be conducted in the next eighteen months involving the existing Spryng®
formulation and other variations to identify and determine the next commercial product(s) that may be administered to the digital cushion
of horses for the treatment of navicular disease.

13

Employees
and Human Capital

As
of July 10, 2025, we have 24 employees. We also engage outside consultants to assist with research and development, clinical development
and regulatory matters, investor relations, operations, and other functions from time to time.

The
Company believes that its success depends on the ability to attract, develop, and retain key personnel. It also believes that the skills,
experience, and industry knowledge of its employees significantly benefit its operations and performance. The Company believes that it
offers competitive compensation and other means of attracting and retaining key personnel. None of our employees are represented by a
labor union and we believe that our relationships with our employees are good.

Insurance

We
currently maintain a “life science” commercial insurance policy with coverage in the amount of $2 million for our products
and operations. The policy has been designed for those engaged in the life science business. We may face claims in excess of the limits
of such insurance. As well, claims made against us may fall outside of our coverage. The policy is a “claims made” policy.
Thus, our coverage must be maintained at the time a claim is made for us to be entitled to seek coverage from the issuer of the policy
for such claims.

Available
Information

We
make available, free of charge and through our Internet website at www